CellWell record HH-580996
Evaluation of the safety and efficacy of 225Ac-PSMA-CY313 in metastatic castration-resistant prostate cancer: preliminary results
Hao Zhang; Yekuan Shi; Yanqin Yu; Zongxi He; Fei Luo; Yue Wu; Tielong Tang; Daiyuan Ma; Suping Li
2026
In plain language
In 16 men with heavily pretreated metastatic castration-resistant prostate cancer, an investigational alpha-emitting PSMA radioligand produced PSA declines of 50% or more in 37.5% with predominantly low-grade xerostomia.
- Evidence
- Established
- Design
- Clinical trial
Cite this record: https://thecellwell.org/studies/HH-580996
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.